The principles guiding the design and synthesis of bioactive compounds based on natural product (NP) structure, such as biology-oriented synthesis (BIOS), are limited by their partial coverage of the NP-like chemical space of existing NPs and retainment of bioactivity in the corresponding compound collections. Here we propose and validate a concept to overcome these limitations by de novo combination of NP-derived fragments to structurally unprecedented 'pseudo natural products'. Pseudo NPs inherit characteristic elements of NP structure yet enable the efficient exploration of areas of chemical space not covered by NP-derived chemotypes, and may possess novel bioactivities. We provide a proof of principle by designing, synthesizing and investigating the biological properties of chromopynone pseudo NPs that combine biosynthetically unrelated chromaneand tetrahydropyrimidinone NP fragments. We show that chromopynones define a glucose uptake inhibitor chemotype that selectively targets glucose transporters GLUT-1 and -3, inhibits cancer cell growth and promises to inspire new drug discovery programmes aimed at tumour metabolism.
T he discovery of novel small-molecule chemotypes with unprecedented or unexpected bioactivity may require the design and synthesis of novel chemical matter, a priori endowed with biological relevance. Corresponding design strategies will be particularly efficient if they draw from previous insight gained with established biologically relevant compound classes, such as natural products (NPs).
Biology oriented synthesis (BIOS) of natural-product-inspired compound classes 1, 2 and related approaches 3 actively embrace this principle. In BIOS, NP scaffolds are structurally simplified to less complex, synthetically accessible scaffolds that retain the characteristic properties, the kind of bioactivity and therefore the biological relevance of the guiding NPs. However, the BIOS approach faces general chemical and biological limitations.
NPs occupy only a relatively small fraction of total NP-like chemical space 4 . However, transcriptionally silent and therefore unexploited biosynthesis pathways exist [5] [6] [7] , and currently operating pathways can be reassembled into new artificial biosynthesis pathways 8 . Thus, inspiration by NP structures, in principle, can go far beyond the scaffolds of the currently known NP classes that define the chemical basis of BIOS. BIOS arrives at compound classes that often retain the kind of bioactivity and therefore most likely the target classes of the guiding NPs, thereby restricting the exploration of biological space 9 . These limitations could possibly be overcome if BIOS was united with a principle that enables efficient synthetic coverage of a larger chemical space, such as fragment-based compound design 10, 11 . We have identified NP fragments that represent NP structure and properties 12 , and NPs themselves may be the size of a fragment 13 or can be degraded to fragment-type compounds 14 . De novo combination of such NP fragments may lead to unprecedented compound classes that inherit characteristic elements of the NP structure and properties, and thus biological relevance, yet go beyond the areas of chemical space explored by nature. Corresponding compound collections will differ fundamentally from BIOS collections and define new classes of NP-inspired compounds. Such conceptually novel pseudo NPs will not be accessible via existing biosynthesis pathways and promise to have unexpected bioactivity and targets.
Here we provide a proof of principle for the pseudo NP concept through the design, synthesis and biological investigation of chromopynones, a pseudo NP class that unites the biosynthetically unrelated chromane 15 and tetrahydropyrimidinone (THPM) NP fragments [16] [17] [18] (Fig. 1a,b) . Biological investigation of a synthesized compound collection revealed that the chromopynones define a truly novel, structurally unprecedented glucose uptake inhibitor chemotype that selectively targets glucose transporters GLUT-1 and GLUT-3 and promises to inspire new drug discovery programmes aimed at the modulation of tumour metabolism.
Results

Design and synthesis of a chromopynone pseudo NP collection.
To design a representative pseudo NP class we considered basic guidelines that we expect to be applicable in a general sense. First, because chirality is a defining property of many NPs, and stereogenic content correlates with bioactivity 19, 20 , it was planned to combine NP fragments in a novel three-dimensional scaffold amenable to efficient synthetic modification and decoration, for example, through a bridge-forming, bipodal connection. In addition, we sought to combine NP fragments with complementary heteroatoms, in particular nitrogen and oxygen, to create structural diversity and a difference from the guiding NPs. As a third design criterion and to maximize the biological relevance of pseudo NPs, we considered combining Chromopynones are pseudo natural product glucose uptake inhibitors targeting glucose transporters GLUT-1 and -3 NP fragments, embedded in NPs with diverse bioactivities. Finally, we reasoned that the combination of biosynthetically unrelated fragments should be beneficial for novel bioactivity, because biosynthetically different NPs will have emerged from biosynthesis cascades composed of different enzymes, so the corresponding NPs will encode different structural parameters for binding to proteins.
NPs embodying chromane or chromene fragments occur widely in nature and are endowed with a multitude of bioactivities (for representative examples see Fig. 1 ) 15 . It was planned to combine this oxygen-rich fragment with a biosynthetically unrelated nitrogen-containing fragment, such as a THPM, which defines the structural core of an antibiotic class 18 . This novel scaffold should contain stereogenic centres and be readily accessible via an efficient synthesis route.
The synthesis of dihydropyrimidinones (DHPM) via a variant of the Biginelli multicomponent reaction can be combined with intramolecular attack by an appended nucleophile ( Fig. 1c and Fig. 2a ), ester hydrolysis, and decarboxylation to a bicyclic scaffold that contains both the chromane and the THPM fragments 21 . We expanded the scope of this stepwise transformation to substituted ureas, and developed a robust, modular and telescoped process requiring only one final chromatographic purification. Acetylated 2-hydroxybenzaldehydes, substituted ureas and methylacetoacetate, in the presence of TMSCl 22 , yielded DHPM intermediates 4 in good yields (76-85%; Supplementary Section 'Experimental for compounds'). Removal of the acetate under mild conditions to induce cyclization, methyl ester hydrolysis with lithium hydroxide and thermal decarboxylation in the presence of lithium salts could readily be combined, resulting in a highly efficient, modular and telescoped one-pot synthesis. The synthesis combines four linear steps, requires minimal handling and has only one late-stage purification step. The intramolecular cyclization is stereospecific, as it can only occur from the same face of the approaching nucleophilic phenol, resulting in the ultimate isolation of products 5 -48 as single diastereomers (see Supplementary Section 'Experimental for compounds' for further details). A range of substituents on the benzaldehydes, including halogens and unsaturated alkyl groups (Supplementary Table 1 , entries 9, 12 and 15), were tolerated. Nucleophilic hydroxyl groups and sulfur nucleophiles did not interfere with the cyclization step, affording the corresponding intermediates in similar yields (Supplementary Table 1 Cheminformatic analyses of the chromopynones. To compare the chemical space occupied by the chromopynones, NP-likeness scores, as introduced in ref. 23 ( Fig. 3a and Supplementary Fig. 12 ), were calculated for the chromopynones, NPs listed in ChEMBL 24 , compound collections synthesized according to BIOS logic (see Supplementary Fig. 3 for structures) and compounds in DrugBank, representing marketed and experimental drugs 25 . The chromopynones display a narrow score distribution in an area that is sparsely covered by NPs and BIOS collections (Fig. 3a) . Therefore, they structurally differ from both those groups. This finding seems counterintuitive, because the chromopynones structurally combine NP fragments. However, the novel combination realized in the chromopynones does not exist in NP scaffolds, which implies that the NP score should be different from those of the majority of NPs. Furthermore, the introduction of nitrogen atoms (in analogy to the higher proportion of N found in drugs 26 compared to NPs) may yield a lower score. In fact, in silico replacement of nitrogen atoms by oxygen or carbon atoms in the scaffold of chromopynone 6 , thereby generating close analogues with different heteroatom composition, results in increasing NP scores ( Supplementary Fig. 2d ). Inclusion of the NP scores calculated for compounds in DrugBank revealed that, despite their differences, chromopynone pseudo NPs and BIOS compounds display NP scores in the range of many approved and experimental drugs. In addition, 84% of the chromopynones fall into the Lipinksi Rule-of-Five space ( Fig. 3b and Supplementary Table 4 ). The design principle whereby an oxygenrich scaffold is combined with a nitrogen-rich fragment may eventually render these pseudo NPs structurally closer to drugs and less related to NP structures. Notably, this drug likeness may also induce advantageous physical properties for drug discovery programmes. This comparison suggests that the properties of the chromopynones are more than merely the sum of the individual NP fragment components. An analysis of the principal moments of inertia (PMIs) 27 of the chromopynones to analyse their molecular shape and size revealed that these compounds display a wide distribution of PMI values, similar to chromane-and THPM-containing NPs, and thus a higher three-dimensional character compared to commercially available compound collections 28 . This observation suggests that the molecular diversity of NPs is conserved through the process of deconstruction into NP-derived fragments and recombination into pseudo NPs.
Collectively, these data suggest that chromopynones have a novel scaffold that lies outside the chemical space covered by NPs. This observation reflects the fact that chromopynones are not accessible via biosynthesis. Chromopynones occupy a distinct portion of chemical space accessible by synthesis guided by the principle of fusing biosynthetically unrelated NP fragments in novel arrangements. These pseudo NPs are endowed with advantageous properties, as they display NP scores similar to those of approved drugs, and the majority of the collection falls into Lipinski space.
Biological investigation of the chromopynones and glucose uptake inhibition. Pseudo NPs may display bioactivities that are very different from those of the individual guiding NPs from which the newly combined fragments were derived. Therefore, this chemocentric approach requires a wider biological activity investigation to reveal potential biological effects, similar to the biological evaluation of newly discovered NPs, which in general are investigated in multiple bioassays to uncover their potential bioactivity. Beyond this experimental approach, in principle the bioactivity of pseudo NPs could be hypothesized by means of current computational target prediction. Such methods could, for instance, suggest known biological targets by comparing NP fragments to synthetic drugs 29 . The necessity of evaluating pseudo NPs in multiple assays to identify novel bioactivity may in the future be overcome by phenotyping based on high-content technologies 30 . Such techniques may efficiently cover larger areas of biological space in one experimental approach, for example leading to quantifiable bioactivity fingerprints for compounds that may indicate particular targets.
Chromopynones were investigated in several cell-based assays to monitor cell signalling, such as the Wnt and Hedgehog pathway, or metabolic processes like autophagy and glucose uptake. These assays monitor macroscopic changes and effects such as reporter gene expression or osteoblast differentiation for the Wnt and Hedgehog pathway, respectively, or LC3 puncta formation following induction of autophagy. This investigation revealed that chromopynones selectively inhibit glucose uptake in HCT116 cells (no activity was observed up to 10 μ M in the other assays). Elevated glucose uptake and aerobic glucose metabolism (glycolytic phenotype) are characteristics of many cancers and contribute to their increased demand for energy and nutrients 31 . Among the Class 1 glucose transporters (GLUT-1-4) 32, 33 , GLUT-1 and -3, in particular, are strongly upregulated in the majority of cancers (lung, brain, breast, bladder, cervical, colorectal, oesophageal, hepatocellular, ovarian, renal cell, pancreatic and prostate cancer, for example) 34 , and have been linked to poor survival and tumour aggressiveness 34, 35 . Therefore, potent and selective small-molecule inhibitors of glucose uptake are in high demand but have only rarely been reported 36, 37 . Eighteen of the 44 chromopynones inhibited uptake of the nonmetabolizable glucose analogue 2-deoxy-glucose (2-DG) 38 , with half-maximum inhibitory concentration (IC 50 ) in the range of 0.9 to 23 μ M (Table 1 and Supplementary Table 1 ) with (± )-chromopynone-1 (compound 11 , Table 1 , entry 2) being most active, with an IC 50 of 0.9 ± 0.4 µ M. The compound did not inhibit downstream hexokinase, thus demonstrating direct interference with glucose uptake (Supplementary Fig. 9 ).
The glucose uptake inhibiting activity was not shared by 2,801 compounds containing the chromane fragment or substructure and by 1,270 compounds containing the THPM fragment or substructure contained in our in-house library (Supplementary Fig. 1) . Thus, the chromopynones constitute independent bioactive entities with bioactivities not shared by the individual NP fragments. Structure-activity relationship for glucose uptake inhibition. For inhibition of glucose uptake by the chromopynones a clear structure-activity relationship emerged. Thus, the substitution pattern around the fused phenyl ring was important for activity and potency ( 40 and 43 ) is disadvantageous. Based on the structure-activity correlation analysis, compound 11 (chromopynone-1) was chosen for further in-depth analysis. Enantiomer separation and independent synthesis utilizing an enantioselective variant of the Biginelli reaction 39 (see Supplementary Section 'Enantioselective Biginelli reaction' for further details) revealed that the (− )-(R,R)-enantiomer (for structure see Fig. 4 ) is more active, with an IC 50 of 412 nM (± 120 nM) for inhibition of 2-DG uptake in HCT116 cells.
GLUT isoform selectivity. Selectivity for inhibition of the two most cancer-relevant glucose transporters, GLUT-1 and -3 40, 41 , was assessed with human colorectal adenocarcinoma DLD-1 cells, which mainly express GLUT-1 and GLUT-3 (as reported by the CCLE database) 42 , and an isogenic cell line DLD-1-GLUT1
(−/−) with homozygous deletion of GLUT1. This cell line expresses GLUT-3 at an approximately threefold higher level than the parent DLD-1 cells (Supplementary Figs. 6 and 7) . (− )-(R,R)-Chromopynone-1 inhibited 2-DG uptake in DLD-1-GLUT1
(−/−) cells with IC 50 = 322 nM and with IC 50 = 162 nM for DLD-1 cells (Fig. 4 and Supplementary Table 2); that is, the compound targets both GLUT-1 and -3.
Selective transient overexpression of GLUT-1 to GLUT-4 in CHO cells should lead to selective increase of IC 50 if the respective overexpressed isoforms were targeted by (− )-(R,R)-chromopynone-1 43 . Overexpression of GLUT-1 or GLUT-3, (Fig. 5b) . The difference in GI 50 values for both cell lines is in agreement with their known different dependency on glucose 44, 45 . These findings indicate that inhibition of glucose uptake by (− )-(R,R)-chromopynone-1 translates into reduced cell growth.
The inhibition of glucose uptake via glucose transporters GLUT-1 and -3 and the fact that chromopynones define an unprecedented glucose uptake inhibitor chemotype provide a proof of principle for the concept that the combination of NP fragments in novel arrangements may enable the exploration of chemical space not covered by currently existing NPs and the identification of novel bioactivities and targets for NP-inspired compounds.
Discussion
We have introduced the concept of combining NP fragments in new arrangements to form pseudo NPs to explore larger areas of NP-like biologically relevant chemical space not covered by nature. Pseudo NPs resemble and contain different elements of NP structure, but are not accessible via existing biosynthetic pathways and promise to have unexpected bioactivity and biological targets. We note that the term 'pseudo natural product' has been used previously by Suga and colleagues to characterize in vitro synthesized cyclopeptides 46, 47 and also by Oshima and colleagues, who intercepted biosynthetic pathways to obtain hybrid alkaloidlike compounds with novel bioactivity 48, 49 . We have validated the pseudo NP concept through the design, synthesis and evaluation of chromopynones, which unite fragments representative of biosynthetically unrelated NPs containing the chromene or chromane structural element 15 , and also the THPM fragment ( Fig. 1 ) 16, 18 . Chromopynone design has an emphasis on stereogenic character, because bioactivity is often correlated with three-dimensional structure 50, 51 , and combining fragments derived from biosynthetically unrelated NPs with complementary heteroatom content can be used to guarantee structural novelty in NPs. Such combinations-not found in nature-should enable the modulation of biological targets (that are not shared by the guiding NPs) and introduce favourable physicochemical properties, in particular balanced hydrophobic and polar character. For example, the chromane fragment contains carbon and oxygen atoms and an aromatic ring, whereas the THPM fragment is aliphatic and introduces nitrogen atoms. Fragment combination was planned to make use of an efficient synthetic strategy that generates stereogenic centres in a complexity-generating manner, to result in the often complex structures of NPs. These design criteria were met by using a variant of the Biginelli multicomponent and multistep reaction cascade, which was combined in a one-pot process with subsequent cyclization and decarboxylation steps to yield a collection of 44 structurally diverse chromopynones.
A comparison of NP scores for the chromopynones, BIOS compound collections, NPs and drugs and drug candidates revealed that the chemical space occupied by the chromopynones differs from the space defined by NPs and BIOS compounds. Their scores instead resemble the NP scores of drugs and comply with the Ruleof-Five. Because the combined fragments represent NP structures, this difference seems unexpected. However, it reflects the fact that this fragment combination is novel; that is, it is not found in nature. This analysis indicates that the de novo combination of biosynthetically unrelated fragments in novel arrangements indeed allows the exploration of areas of NP-like chemical space that are not or are only sparsely covered by NPs. Combining NP fragments with different heteroatom content appears to be particularly important; in other words, oxygen-rich (as found more frequently in NPs than in drugs) combined with nitrogen-rich (as found more frequently in drugs) fragments. Future pseudo NP design, in general, might favour such combinations, for example, novel combinations of alkaloid-with terpene-or polyketide fragments.
Biological investigation of the chromopynones in different cell-based assays-monitoring biological signalling and metabolic processes-revealed that members of this pseudo NP class selectively inhibit glucose uptake in cells. Compounds with chromane or THPM structure only did not inhibit glucose uptake, demonstrating that this novel bioactivity is the result of fragment combination. Subsequent target validation experiments revealed that the most potent compound, termed (− )-(R,R)-chromopynone-1, selectively and potently targets glucose transporters GLUT-1 and -3 and thereby inhibits tumour cell growth.
Many cancers feature an increased demand for glucose to meet their bioenergetic and biosynthetic requirements and therefore upregulate the expression of glucose transporter expression, in particular GLUT-1 and -3 35 . Inhibition of glucose uptake has been proposed as a novel avenue for the treatment of cancer, and novel GLUT inhibitors are in great demand. Very recently, potent small molecules targeting GLUTs, including a selective GLUT-1 inhibitor, have been described 37 . However, inhibitors simultaneously and selectively targeting GLUT-1 and -3 may be most advantageous and even required for full efficacy 52 , yet dual selective GLUT-1/-3 inhibitors have not been reported so far.
(− )-(R,R)-Chromopynone-1 comprises a structurally novel, unprecedented GLUT inhibitor with the desired selectivity.
Our results provide a proof of principle for the concept of combining compound collection synthesis based on biological relevance (that is, BIOS) with fragment-based compound discovery to inspire the design and synthesis of biologically relevant pseudo NP collections with both novel NP-like structure and novel bioactivity. Pseudo NPs retain the characteristic structural elements of NP scaffolds as well as NP properties, but they allow the exploration of uncharted areas of NP-inspired chemical space, and expansion of the target space accessible to NP-inspired compounds. The chromopynone example demonstrates that pseudo NPs may be accessible by rapid and efficient chemical synthesis, and that pseudo NPs can yield modulators of protein function with unprecedented chemotype. The discovery that the chromopynone pseudo NPs define a novel glucose uptake inhibitor chemotype that selectively targets the glucose transporters GLUT-1 and GLUT-3 and thereby inhibits tumour cell growth promises to inspire new drug discovery programmes aimed at the modulation of tumour metabolism.
Methods
General method for the preparation of chromopynones. In a typical example, trimethylchlorosilane (770 μ l, 6 mmol, 6 equiv.) was added dropwise to a stirred solution of urea (1 mmol, 1 equiv.), aldehyde (1 mmol, 1 equiv.) and methylacetoacetate (180 μ l, 1.5 mmol, 1.5 equiv.) in DMF (1 ml, 1 M), and the resulting mixture was stirred at r.t. After 18 h, the reaction was quenched with H 2 O (2 ml) and diluted with EtOAc (40 ml). The organic layer was washed sequentially with H 2 O (5 × 20 ml), LiCl solution (sat. aq., 1 × 20 ml) and NaCl solution (sat. aq., 1 × 20 ml), dried over Na 2 SO 4 , filtered, and concentrated in vacuo to give a crude product. Saturated NaHCO 3 aq. solution (10 ml) was added to a stirred solution of the crude DHPM in MeOH (10 ml) and the resulting suspension was heated to 40 °C. After 16 h, the reaction mixture was allowed to cool to r.t. and was concentrated in vacuo. The crude was diluted with THF-H 2 O (1:1, 10 ml, 0.1 M), LiOH (15 equiv.) was added, and the reaction mixture was heated to 40 °C. After 18 h, the reaction mixture was allowed to cool to r.t. and was concentrated in vacuo to half volume. The reaction mixture was acidified to pH 1-2 by slow addition of 1 M HCl (aq.) solution and heated to 80 °C (probe temperature of 82 °C). After 6 h, the reaction mixture was allowed to cool to r.t. and extracted with CHCl 3 -MeOH (8:2, 5 × 20 ml). The combined organic layers were dried over Na 2 SO 4 The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
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Replication
For the 2-DG and Hexokinase assay: three biological replicates (performed on different days), each performed in triplicate. All attempts at replication were successful Randomization Each compound tested was added to a random set of triplicate rows of the respective well-plate.
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High-throughput screening was performed using robot liquid handler and in specific cases e.g. for compound 11, the 2-DG assay was repeated by investigators.
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